Polansky Develops AI Model Using Living Human Skin for Skincare Research

Michael Polansky, long known as Lady Gaga’s partner and a former senior aide to tech entrepreneur Sean Parker, has quietly developed an artificial‑intelligence‑driven biotechnology venture that preserves living human skin tissue outside the body for extended periods. The company, which has kept its operations low‑profile, now announces its first public launch, positioning itself to accelerate the discovery of novel skincare compounds.

Polansky’s platform employs machine‑learning algorithms to monitor and maintain the viability of cultured skin samples, allowing researchers to observe cellular responses to a wide array of chemical agents over weeks rather than days. By extending the lifespan of these tissues, the startup aims to reduce reliance on animal testing and speed the development of safer, more effective dermatological products. The move comes at a time of heightened interest in AI‑augmented drug discovery and a growing demand for sustainable, human‑based testing methods.

The public unveiling signals a shift from Polansky’s previous high‑profile tech roles to a focus on medical innovation. Industry observers note that the company’s approach could streamline the pipeline from compound screening to clinical evaluation, potentially shortening the time required to bring new skincare solutions to market. As the venture steps into the spotlight, stakeholders will be watching to see how its technology performs in real‑world applications and whether it can deliver on its promise of more rapid, humane discovery of dermatological therapeutics.